A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01771455PMCID PMC11038481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

  1989cited by this paper
• Recombinant interferon‐γ lacks activity against metastatic colorectal cancer but increases serum levels of ca 19‐9

  1989cited by this paper
• Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity.

  1989cited by this paper
• Interleukin-2: inception, impact, and implications.

  1988cited by this paper
• Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.

  1988cited by this paper
• Interferon-gamma, the activated macrophage, and host defense against microbial challenge.

  1988cited by this paper
• Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.

  1988cited by this paper
• Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects.

  1988cited by this paper
• Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

  1988cited by this paper
• Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response.

  1988cited by this paper
• Transport of molecules in the tumor interstitium: a review.

  1987cited by this paper
• Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.

  1987cited by this paper
• Concurrent enhancement of monocyte immunoregulatory properties and effector functions by recombinant interferon-gamma.

  1986cited by this paper
• Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.

  1986cited by this paper
• The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors.

  1986cited by this paper
• Enhanced Expression of Surface Tumor Associated Antigens on Human Breast and Colon Tumor Cells by Recombinant Human Interferon

  1985cited by this paper
• Widespread and selective induction of major histocompatibility complex- determined antigens in vivo by gamma interferon

  1985cited by this paper
• A clinical trial of anti-idiotype therapy for B cell malignancy.

  1985cited by this paper
• Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide.

  1985influential reference
• Human Immune Responses to Murine Monoclonal Antibodies

  1985cited by this paper
• Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2.

  1984cited by this paper
• Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

  1984cited by this paper
• Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients.

  1984cited by this paper
• Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia.

  1984cited by this paper
• Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.

  1984cited by this paper
• Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.

  1984cited by this paper
• Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells.

  1983cited by this paper
• Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer.

  1983cited by this paper
• Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

  1982cited by this paper
• Preferential effect of γ interferon on the synthesis of HLA antigens and their mRNAs in human cells

  1982cited by this paper
• Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

  1982cited by this paper
• Monoclonal antibodies in cell‐mediated cytotoxicity against human melanoma and colorectal carcinoma

  1979cited by this paper
• Implications of immunological heterogeneity of tumours

  1979cited by this paper

• Fifty years of monoclonals: the past, present and future of antibody therapeutics

  2025cites this paper
• Therapeutic cancer vaccines.

  2017cites this paper
• Mammalian cell display technology coupling with AID induced SHM in vitro: an ideal approach to the production of therapeutic antibodies.

  2014cites this paper
• Anticuerpos Monoclonales como Terapia Antineoplásica

  2014cites this paper
• Principles of Cancer Biotherapy 5

  2013cites this paper
• This information is current as T Cells + and CD 4 + Tumor Cells by CD 8 Prostate Stem Cell Antigen-Expressing Bispecific Antibodies Mediate Killing of Novel Humanized and Highly Efficient

  2012cites this paper
• Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells

  2012cites this paper
• Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

  2011cites this paper
• Generation of a Recombinant Full-Length Human Antibody Binding to Botulinum Neurotoxin A

  2010cites this paper
• Biological therapy of colon cancer

  2009cites this paper
• Monoclonal antibody therapy

  2009cites this paper
• Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses.

  2007cites this paper
• Target Therapy for Colorectal Cancer

  2006cites this paper
• Immuntherapie des Kolorektalkarzinoms - aktueller Stand und Perspektiven

  2006cites this paper
• Generation of human antibody fragments against Streptococcus mutans using a phage display chain shuffling approach

  2005cites this paper
• Expression of epithelial-cell adhesion molecule (Ep-CAM) in small cell lung cancer as defined by monoclonal antibodies 17-1A and BerEP4

  2005cites this paper
• Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays

  2005cites this paper
• Monoclonal antibodies in the treatment of colorectal cancer.

  2004cites this paper
• Edrecolomab (Monoclonal Antibody 17-1A)

  1998cites this paper
• Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies

  1995cites this paper
• Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody

  1992cites this paper